These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

80 related items for PubMed ID: 8210789

  • 1. Case management of the hospitalized patient receiving interleukin-2.
    Sharp E.
    Semin Oncol Nurs; 1993 Aug; 9(3 Suppl 1):14-9. PubMed ID: 8210789
    [Abstract] [Full Text] [Related]

  • 2. [Interleukin 2 based ambulatory therapy of metastatic renal cell carcinoma].
    Atzpodien J, Kirchner H, Poliwoda H.
    Med Klin (Munich); 1996 Apr 12; 91 Suppl 3():38-43. PubMed ID: 8692118
    [Abstract] [Full Text] [Related]

  • 3. Interleukin-2 therapy for renal cell cancer: indications, effects, and nursing implications.
    Letizia M, Conway AM.
    Crit Care Nurse; 1996 Oct 12; 16(5):20-6, 30-2, 34-5. PubMed ID: 9004585
    [No Abstract] [Full Text] [Related]

  • 4. Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma.
    Thompson JA, Curti BD, Redman BG, Bhatia S, Weber JS, Agarwala SS, Sievers EL, Hughes SD, DeVries TA, Hausman DF.
    J Clin Oncol; 2008 Apr 20; 26(12):2034-9. PubMed ID: 18347008
    [Abstract] [Full Text] [Related]

  • 5. Changes in biochemical laboratory investigation in patients treated with constant infusion recombinant interleukin-2.
    Ubhi SS, Horsburgh T, Veitch PS, Bell PR.
    Anticancer Res; 1991 Apr 20; 11(6):2059-62. PubMed ID: 1776840
    [Abstract] [Full Text] [Related]

  • 6. A comparison of systemic versus inhaled recombinant IL-2 administration for the treatment of metastatic renal cell carcinoma.
    Huland E, Heinzer H, Huland H.
    Folia Biol (Praha); 2000 Apr 20; 46(6):241-50. PubMed ID: 11140857
    [Abstract] [Full Text] [Related]

  • 7. Immunotherapy of pulmonary metastatic renal cell carcinoma: success dependant on risk factors?
    Huland E, Heinzer H, Huland H.
    Hepatogastroenterology; 1999 May 20; 46 Suppl 1():1257-62. PubMed ID: 10429971
    [Abstract] [Full Text] [Related]

  • 8. Multiple pulmonary metastases from renal cell carcinoma treated effectively by recombinant interleukin-2.
    Ikemoto S, Nakatani T, Sugimura K, Tanaka H, Maekawa M.
    Urol Int; 1990 May 20; 45(1):54-7. PubMed ID: 2305497
    [Abstract] [Full Text] [Related]

  • 9. Role of interleukin-2 alone in disseminated renal cell carcinoma: an update.
    Javadpour N, Lalehzarian M.
    Prog Clin Biol Res; 1989 May 20; 303():671-9. PubMed ID: 2789391
    [No Abstract] [Full Text] [Related]

  • 10. Strategies to reduce side effects of interleukin-2: evaluation of the antihypotensive agent NG-monomethyl-L-arginine.
    Kilbourn RG, Fonseca GA, Trissel LA, Griffith OW.
    Cancer J Sci Am; 2000 Feb 20; 6 Suppl 1():S21-30. PubMed ID: 10685654
    [Abstract] [Full Text] [Related]

  • 11. Granulocyte-macrophage-colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma: results of two phase II clinical trials.
    Ryan CW, Vogelzang NJ, Dumas MC, Kuzel T, Stadler WM.
    Cancer; 2000 Mar 15; 88(6):1317-24. PubMed ID: 10717612
    [Abstract] [Full Text] [Related]

  • 12. Treatment of pulmonary metastatic renal-cell carcinoma in 116 patients using inhaled interleukin-2 (IL-2).
    Huland E, Heinzer H, Huland H.
    Anticancer Res; 1999 Mar 15; 19(4A):2679-83. PubMed ID: 10470219
    [Abstract] [Full Text] [Related]

  • 13. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
    Hidalgo OF, Aramendía JM, Alonso G, Foncillas JG, Brugarolas A.
    Rev Med Univ Navarra; 1996 Mar 15; 40(3):6-12. PubMed ID: 9499820
    [Abstract] [Full Text] [Related]

  • 14. [Bacteremia caused by Streptococcus equisimilis in a neoplastic patient treated with recombinant interleukin 2].
    Pedro-Botet ML, Ribelles Entrena N, Carrasco Miserachs I, Carles Galcerán J, Sabria-Leal M, Arnal J.
    Enferm Infecc Microbiol Clin; 1990 Dec 15; 8(10):659-60. PubMed ID: 2098130
    [No Abstract] [Full Text] [Related]

  • 15. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients.
    Figlin R, Gitlitz B, Franklin J, Dorey F, Moldawer N, Rausch J, deKernion J, Belldegrun A.
    Cancer J Sci Am; 1997 Dec 15; 3 Suppl 1():S92-7. PubMed ID: 9457402
    [Abstract] [Full Text] [Related]

  • 16. Clinical pathways for managing patients receiving interleukin 2.
    Mavroukakis SA, Muehlbauer PM, White RL, Schwartzentruber DJ.
    Clin J Oncol Nurs; 2001 Dec 15; 5(5):207-17. PubMed ID: 11905416
    [Abstract] [Full Text] [Related]

  • 17. Future expectations for critical care nurses. Competence in immunotherapy.
    Byram DA.
    Crit Care Nurs Clin North Am; 1989 Dec 15; 1(4):797-806. PubMed ID: 2697228
    [Abstract] [Full Text] [Related]

  • 18. Treatment with pentoxifylline and ciprofloxacin reduces the toxicity of high-dose interleukin-2 and lymphokine-activated killer cells.
    Thompson JA, Benyunes MC, Bianco JA, Fefer A.
    Semin Oncol; 1993 Dec 15; 20(6 Suppl 9):46-51. PubMed ID: 8284692
    [No Abstract] [Full Text] [Related]

  • 19. Retrospective review in patients with pulmonary metastases of renal cell carcinoma receiving inhaled recombinant interleukin-2.
    Esteban-González E, Carballido J, Navas V, Torregrosa Z, Muñoz A, de Mon MA, PortugueseSpanish Inhaled IL-2 Group.
    Anticancer Drugs; 2007 Mar 15; 18(3):291-6. PubMed ID: 17264761
    [Abstract] [Full Text] [Related]

  • 20. Advances in management of disseminated renal cell carcinoma.
    Javadpour N.
    Prog Clin Biol Res; 1988 Mar 15; 277():85-91. PubMed ID: 3263656
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.